Pharmacology Book

http://www.fpnotebook.com/

Pharmaceutical Representatives

Aka: Pharmaceutical Representatives, Drug Rep, Prescribing Cost, Sunshine Act
  1. Research: Studies
    1. Evaluation of 446 physicians surveyed
      1. Higher Prescribing Cost risks
        1. Pharmaceutical representative exposure
        2. Group practice setting
      2. References
        1. Caudill (1996) Arch Fam Med 5:201-6 [PubMed]
    2. Direct drug advertising to healthcare consumers
      1. Appears to increase sale of drugs
      2. May result in appropriate prescribing practices
      3. Mintzes (2002) BMJ 324:278-9 [PubMed]
    3. Pharmaceutical samples raise overall Prescribing Costs
      1. Symm (2006) J Am Board Fam Med 19(5): 443-9 [PubMed]
    4. Poorest patients are the least likely to receive free drug samples
      1. Typical drug sample recipient has health insurance and lives far above poverty line
      2. Cutrona (2008) Am J Public Health 98(2): 284-9 [PubMed]
    5. >25% ($16 billion) of drug company advertising ($57 billion) was spent on samples (2004)
      1. Gagnon (2008) PLoS Med 5(1): e1 [PubMed]
  2. Precautions: Gifts
    1. Sunshine Act (U.S. regulation as of August 2013)
      1. Pharmaceutical representative gifts over $10 are reported to a public list (with the provider's name)
  3. Resources
    1. No Free Lunch
      1. http://nofreelunch.org
  4. References
    1. Dachs (2009) Am Fam Physician 79(10): 891-4 [PubMed]

You are currently viewing the original 'fpnotebook.com\legacy' version of this website. Internet Explorer 8.0 and older will automatically be redirected to this legacy version.

If you are using a modern web browser, you may instead navigate to the newer desktop version of fpnotebook. Another, mobile version is also available which should function on both newer and older web browsers.

Please Contact Me as you run across problems with any of these versions on the website.

Navigation Tree